Ozempic Manufacturer Says Consolidation In MDL Is Appropriate
WASHINGTON, D.C. — Novo Nordisk A/S, the manufacturer of Ozempic, tells the U.S. Judicial Panel for Multidistrict Litigation (JPMDL) that consolidation of cases from consumers who allege that they suffered gastrointestinal...To view the full article, register now.
Already a subscriber? Click here to view full article